Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations
Research output: Contribution to journal › Journal article › Research › peer-review
In clinical trials, immunopotentiating reconstituted influenza virosomes (IRIVs) have shown great potential as a versatile antigen delivery platform for synthetic peptides derived from Plasmodium falciparum antigens. This study describes the immunogenicity of a virosomally-formulated recombinant fusion protein comprising domains of the two malaria vaccine candidate antigens MSP3 and GLURP.
| Original language | English |
|---|---|
| Journal | Malaria Journal |
| Volume | 10 |
| Pages (from-to) | 359 |
| ISSN | 1475-2875 |
| DOIs | |
| Publication status | Published - 2011 |
- Adjuvants, Immunologic, Animals, Antibodies, Protozoan, Antigens, Protozoan, Cross Reactions, Immunoglobulin G, Injections, Intramuscular, Malaria Vaccines, Mannitol, Mice, Oleic Acids, Plasmodium falciparum, Protozoan Proteins, Recombinant Fusion Proteins, Vaccines, Synthetic, Vaccines, Virosome
Research areas
ID: 37835014